CN102812040A - Sorf构建体和多基因表达 - Google Patents

Sorf构建体和多基因表达 Download PDF

Info

Publication number
CN102812040A
CN102812040A CN2010800611344A CN201080061134A CN102812040A CN 102812040 A CN102812040 A CN 102812040A CN 2010800611344 A CN2010800611344 A CN 2010800611344A CN 201080061134 A CN201080061134 A CN 201080061134A CN 102812040 A CN102812040 A CN 102812040A
Authority
CN
China
Prior art keywords
intein
protein
polypeptide
expression
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800611344A
Other languages
English (en)
Chinese (zh)
Inventor
G·R·卡森
W·R·焦恩
Y·Z·库尼斯
W·F·莱斯三世
R·A·戴维斯-泰伯
E·冯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN102812040A publication Critical patent/CN102812040A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800611344A 2009-10-30 2010-10-28 Sorf构建体和多基因表达 Pending CN102812040A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25654409P 2009-10-30 2009-10-30
US61/256,544 2009-10-30
PCT/US2010/054475 WO2011053699A1 (en) 2009-10-30 2010-10-28 Sorf constructs and multiple gene expression

Publications (1)

Publication Number Publication Date
CN102812040A true CN102812040A (zh) 2012-12-05

Family

ID=43431207

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800611344A Pending CN102812040A (zh) 2009-10-30 2010-10-28 Sorf构建体和多基因表达

Country Status (13)

Country Link
US (1) US20110150861A1 (enExample)
EP (1) EP2493923A1 (enExample)
JP (1) JP2013509188A (enExample)
KR (1) KR20120091251A (enExample)
CN (1) CN102812040A (enExample)
AU (1) AU2010313395A1 (enExample)
CA (1) CA2776990A1 (enExample)
IL (1) IL219022A0 (enExample)
IN (1) IN2012DN03281A (enExample)
MX (1) MX2012005117A (enExample)
RU (1) RU2012122240A (enExample)
TW (1) TW201124535A (enExample)
WO (1) WO2011053699A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107390A (zh) * 2021-11-05 2022-03-01 中国科学院精密测量科学与技术创新研究院 一种用于表达抗体IgG1的rAAV载体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078433A1 (en) * 2011-11-23 2013-05-30 University Of Hawaii Auto-processing domains for polypeptide expression
US10066019B2 (en) 2012-10-12 2018-09-04 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
US11103932B2 (en) 2018-09-17 2021-08-31 Korea Institute Of Machinery & Materials Cutting head operated by centrifugal force and cutting apparatus including the same
JP7692897B2 (ja) 2019-09-10 2025-06-16 オブシディアン セラピューティクス， インコーポレイテッド 調節可能な制御のためのｃａ２－ｉｌ１５融合タンパク質
EP4100518A4 (en) * 2020-02-07 2024-06-05 The Children's Medical Center Corporation Large gene vectors and delivery and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
CN101356275A (zh) * 2005-11-08 2009-01-28 Eth苏黎世公司 利用多基因重组表达多蛋白复合物

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455275B1 (en) * 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
DE3885431D1 (de) * 1987-12-23 1993-12-09 Boehringer Ingelheim Int Expression der viral kodierten Protease P2A des HRV2.
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5162601A (en) * 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US5519164A (en) * 1990-02-01 1996-05-21 Hoechst Aktiengesellschaft Expression of a multigene RNA having self-splicing activity
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
PT642577E (pt) 1992-05-22 2004-08-31 Univ Montana State Anticorpos com especificidade para moleculas de adesao multipla
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US5496714A (en) * 1992-12-09 1996-03-05 New England Biolabs, Inc. Modification of protein by use of a controllable interveining protein sequence
US5834247A (en) * 1992-12-09 1998-11-10 New England Biolabs, Inc. Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
GB9326271D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Expression of self-processing polyprotein in transgenic plants
US5643745A (en) * 1994-02-03 1997-07-01 University Of Hawaii Heterologous dimeric proteins produced in heterokaryons
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5955072A (en) * 1994-07-13 1999-09-21 Sankyo Company, Limited Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
WO1996013583A2 (en) * 1994-10-20 1996-05-09 Morphosys Gesellschaft Für Proteinoptimierung Mbh Targeted hetero-association of recombinant proteins to multi-functional complexes
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5912167A (en) * 1995-06-06 1999-06-15 Wisconsin Alumni Research Foundation Autocatalytic cleavage site and use thereof in a protein expression vector
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
EP0917585B1 (en) * 1996-07-22 2007-04-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Vectors for delivering viral and oncogenic inhibitors
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US5981182A (en) * 1997-03-13 1999-11-09 Albert Einstein College Of Medicine Of Yeshiva University Vector constructs for the selection and identification of open reading frames
DE69824859T2 (de) * 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
US6933378B2 (en) * 1997-05-30 2005-08-23 Joseph Atabekov Methods for coexpression of more than one gene in eukaryotic cells
US7007589B1 (en) 1997-09-15 2006-03-07 R. Sanderson Management, Inc. Piston assembly
FR2782325B1 (fr) * 1998-08-12 2002-05-24 Proteus Procede d'identification de sequences polynucleotidiques et/ou des proteines correspondantes a partir d'un echantillon d'acides nucleiques
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
US6537806B1 (en) * 1998-06-02 2003-03-25 University Of Washington Compositions and methods for treating diabetes
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
IL143027A0 (en) * 1998-11-16 2002-04-21 Genway Biotech Inc Generation of antibodies using polynucleotide vaccination in avian species
US6365377B1 (en) * 1999-03-05 2002-04-02 Maxygen, Inc. Recombination of insertion modified nucleic acids
CA2365981A1 (en) * 1999-03-24 2000-09-28 Board Of Regents, The University Of Texas System Linear and circular expression elements
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6933362B1 (en) * 1999-08-17 2005-08-23 Rensselaer Polytechnic Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
EP1222298B1 (en) * 1999-10-13 2005-12-07 Immunex Corporation Vectors and methods for recombinant protein expression
WO2001034816A1 (en) * 1999-10-29 2001-05-17 Kosan Biosciences, Inc. Rapamycin analogs
US6665567B2 (en) * 2000-01-14 2003-12-16 Rainer R. Iraschko Optical-ring integer linear program formulation
DE60140996D1 (de) * 2000-02-11 2010-02-25 Metabolix Inc Intein enthaltende multigen-expressionskonstrukte
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
AU2001247296A1 (en) 2000-03-06 2001-09-17 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides
WO2001071004A2 (en) * 2000-03-17 2001-09-27 Incyte Genomics, Inc. Proteases
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6908751B2 (en) * 2000-04-26 2005-06-21 Zymogenetics, Inc. Methods for enhancing the expression of a protein of interest by recombinant host cells
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US6852510B2 (en) * 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US20030036643A1 (en) 2000-09-14 2003-02-20 Jin Cheng He Methods and compositions for the construction and use of fusion libraries
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US20040191786A1 (en) * 2001-02-16 2004-09-30 Yue David T. Three cube fret method (3-fret) for detecting fluorescence energy transfer
EP1368483B1 (en) * 2001-03-09 2012-10-24 Genentech, Inc. Process for production of polypeptides
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
US20040180415A1 (en) * 2001-05-15 2004-09-16 Tchaga Grigoriy S. Methods and compositions for protein purification
US7052905B1 (en) * 2001-08-13 2006-05-30 University Of Kentucky Research Foundation Methods and composition for expressing multiple genes in plants by alternate splicing of a polycistronic message
EP1288891A1 (en) * 2001-08-27 2003-03-05 Hewlett-Packard Company Process and apparatus for displaying data in a specific area of the display in a computer or in an interactive terminal under control of the LAN card and independently on the operating system
AU2002361589A1 (en) * 2001-11-06 2003-05-19 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
US20030157641A1 (en) * 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
CN1263860C (zh) * 2002-09-30 2006-07-12 华南农业大学 多基因载体的构建方法与应用
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
ATE524559T1 (de) * 2002-12-18 2011-09-15 Chromagenics Bv Methode zur verbesserung der proteinproduktion
US7223390B2 (en) * 2003-05-09 2007-05-29 Research Development Foundation Insertion of furin protease cleavage sites in membrane proteins and uses thereof
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
EP1651664B9 (en) * 2003-08-05 2012-03-21 Almac Sciences (Scotland) Limited Ligation method
EP1687328B1 (en) 2003-10-24 2010-03-31 Amgen, Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
US20090098611A1 (en) 2004-02-27 2009-04-16 Wood David W Self-cleaving affinity tags and methods of use
JP2008506389A (ja) * 2004-07-13 2008-03-06 セル ジェネシス インコーポレイテッド Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CN101292036B (zh) * 2005-10-21 2016-04-13 弗·哈夫曼-拉罗切有限公司 用于重组表达多肽的方法
EP2106446A4 (en) * 2007-01-10 2010-06-16 Univ Saskatchewan STABILIZATION OF CYCLIC PEPTIDE STRUCTURES
CA2681581A1 (en) * 2007-03-30 2008-10-09 Abbott Laboratories Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
CN101356275A (zh) * 2005-11-08 2009-01-28 Eth苏黎世公司 利用多基因重组表达多蛋白复合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIXIN CHEN ET AL.: "Protein Splicing in the Absence of an Intein Penultimate Histidine", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107390A (zh) * 2021-11-05 2022-03-01 中国科学院精密测量科学与技术创新研究院 一种用于表达抗体IgG1的rAAV载体及其应用
CN114107390B (zh) * 2021-11-05 2023-10-24 中国科学院精密测量科学与技术创新研究院 一种用于表达抗体IgG1的rAAV载体及其应用

Also Published As

Publication number Publication date
KR20120091251A (ko) 2012-08-17
JP2013509188A (ja) 2013-03-14
IN2012DN03281A (enExample) 2015-10-23
EP2493923A1 (en) 2012-09-05
US20110150861A1 (en) 2011-06-23
CA2776990A1 (en) 2011-05-05
WO2011053699A1 (en) 2011-05-05
MX2012005117A (es) 2012-06-14
TW201124535A (en) 2011-07-16
AU2010313395A1 (en) 2012-05-10
IL219022A0 (en) 2012-06-28
RU2012122240A (ru) 2013-12-10

Similar Documents

Publication Publication Date Title
JP2012235782A (ja) Ｓｏｒｆ構築物並びにポリタンパク質、プロタンパク質及びタンパク質分解による方法を含む複数の遺伝子発現
CN101848936A (zh) 生产方法
JP6087148B2 (ja) タンパク質の生産方法
CN102812040A (zh) Sorf构建体和多基因表达
CN114026224B (zh) 具有sirt-1基因敲除的哺乳动物细胞系
JP2023036934A (ja) リコンビナーゼ媒介性カセット交換を使用した多重特異性抗体スクリーニング法
JP2021516961A (ja) 遺伝子組換え単鎖免疫グロブリン
JP2019503179A (ja) ハイブリッドプロモーターおよびその使用
JP7410983B2 (ja) Ｃｒｅ ｍＲＮＡを使用した標的指向性組込みによるタンパク質発現細胞の作製のための方法
JP7446342B2 (ja) 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
JP7572977B2 (ja) 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
JP2022537202A (ja) 所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法
JP2022537338A (ja) 所定の構成の複数の発現カセットの標的指向性組込みによって二価二重特異性抗体発現細胞を作製するための方法
TW202430639A (zh) 增加重組蛋白表現之方法
US20210139599A1 (en) Recombinant immunoglobulins of a new igg5 class, encoded by the human heavy chain pseudo-gamma gene
HK40052669A (en) Multispecific antibody screening method using recombinase mediated cassette exchange
HK40061338A (en) Mammalian cell lines with sirt-1 gene knockout
HK40060851B (zh) 通过使用cre mrna进行的靶向整合来产生蛋白质表达细胞的方法
HK40060850A (en) Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
HK40060851A (en) Method for the generation of a protein expressing cell by targeted integration using cre mrna
HK40061221A (en) Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
HK1225043A1 (en) Expression constructs and methods for expressing polypeptides in eukaryotic cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130619

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130619

Address after: Illinois State

Applicant after: ABBVIE company

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121205